Eli Lilly shares surged 9.5% after beating Q4 expectations and providing a strong 2026 forecast driven by demand for weight-loss drugs Mounjaro and Zepbound. Revenue hit $19.29 billion, up 43% YoY, with adjusted EPS of $7.54. Full-year guidance predicts revenue of $80-83 billion and EPS of $33.50-35.

Mounjaro and Zepbound led growth, generating $7.41 billion and $4.26 billion in sales respectively, exceeding expectations. Q4 2025 revenue increased 43% on volume growth from these weight-loss drugs. Eli Lilly’s gross margin was 82.5% with R&D expenses at $3.8 billion and marketing costs at $3.1 billion.

Read more at Yahoo Finance: Eli Lilly shares soar after Q4 beat, strong forecast on weight-loss drugs